# Haematopoietic Growth Factors G-CSF and Erythropoietin

> G-CSF and erythropoietin for NEET-PG Medicine, covering indications, adverse effects, stem cell mobilisation and causes of erythropoietin hyporesponsiveness.

- Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/growth-factors-g-csf-and-erythropoietin
- Exam / course: NEET-PG · Subject: Medicine
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-14
- Last updated: 2026-10-14
- Reference basis: Harrison's Principles of Internal Medicine; Goodman and Gilman's The Pharmacological Basis of Therapeutics
- How to cite: "Haematopoietic Growth Factors G-CSF and Erythropoietin", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/growth-factors-g-csf-and-erythropoietin

## Direct answer

Granulocyte colony-stimulating factor (G-CSF) and erythropoietin are recombinant haematopoietic growth factors, with G-CSF shortening neutropenia and erythropoietin raising haemoglobin. G-CSF is used for febrile neutropenia prophylaxis and stem cell mobilisation, while erythropoietin treats anaemia of chronic kidney disease and selected chemotherapy-related anaemia. Bone pain is the commonest adverse effect of G-CSF, and hypertension and thrombosis are the key risks of erythropoietin.

## What you must remember

- **G-CSF products:** filgrastim and pegfilgrastim, along with their biosimilars, stimulate neutrophil production and shorten the duration of neutropenia.
- **Primary prophylaxis threshold:** G-CSF is commonly given from the first cycle when a regimen carries a febrile neutropenia risk of around 20 per cent or more.
- **G-CSF adverse effects:** bone pain is commonest; splenic rupture is rare but serious, and acute respiratory distress is reported rarely.
- **Stem cell mobilisation:** G-CSF moves CD34-positive stem cells into the blood, allowing apheresis collection for transplant.
- **Erythropoietin products:** epoetin alfa and darbepoetin alfa treat anaemia of chronic kidney disease and selected chemotherapy-induced anaemia.
- **ESA risks:** hypertension, thrombosis, stroke and seizures, with haemoglobin kept near the target rather than above about 11 to 12 g/dL.
- **Hyporesponsiveness:** iron deficiency, inflammation, hyperparathyroidism, aluminium toxicity, hypothyroidism and haemolysis blunt the response.

## Choosing and monitoring a growth factor

The two agents are chosen for different goals, and each needs its own checks. The steps below move from the target, through the prerequisites, to monitoring and stopping rules.

1. **Define the target.** Neutrophil recovery points to G-CSF, while haemoglobin correction points to erythropoietin, and the two are not interchangeable.
2. **Assess neutropenia risk.** Regimens with a risk of around 20 per cent or more justify primary G-CSF, and intermediate-risk regimens depend on patient factors such as age and comorbidity.
3. **Check iron status.** Ferritin and transferrin saturation should be adequate, because erythropoietin cannot work well in iron deficiency.
4. **Follow the label and protocol.** Dosing and timing come from the product label and the centre's protocol rather than from memory.
5. **Monitor the response.** Neutrophil counts track G-CSF effect, while haemoglobin and blood pressure are checked at regular intervals during erythropoietin therapy.
6. **Watch for toxicity and stop rules.** Erythropoietin is held if haemoglobin rises too fast or exceeds the target, and left upper abdominal pain on G-CSF prompts a search for splenic injury.

## Where the exam tries to catch you

Questions test whether the target is clear and whether the common complication is named correctly.

- **Trap:** Erythropoietin is given to bring haemoglobin to a normal level. **Correct:** the aim is the lowest dose that avoids transfusion, because haemoglobin above about 11 to 12 g/dL increases thrombotic and stroke risk.
- **Trap:** A poor erythropoietin response is treated by raising the dose. **Correct:** iron deficiency, inflammation, hyperparathyroidism and aluminium are sought first, since they blunt the response.
- **Trap:** Splenic rupture is the commonest complication of G-CSF. **Correct:** bone pain is the common complaint, and splenic rupture is rare but must be considered in left upper quadrant pain.

## Frequently asked questions

### What is the main indication for G-CSF in chemotherapy?

G-CSF is used mainly for primary or secondary prophylaxis of febrile neutropenia during myelosuppressive chemotherapy. Primary prophylaxis is commonly considered when the regimen carries a febrile neutropenia risk of around 20 per cent or more.

### What is the commonest adverse effect of filgrastim?

Bone pain is the commonest adverse effect of filgrastim and other G-CSF products, usually managed with analgesia. Splenic rupture is a rare but serious complication, and it should be considered in left upper quadrant pain.

### Why does erythropoietin fail to correct anaemia in some patients?

Erythropoietin hyporesponsiveness is most often caused by iron deficiency, inflammation, hyperparathyroidism, aluminium toxicity or hypothyroidism. Correcting these causes and checking iron stores is the first step before the erythropoietin dose is increased.

### Which adverse effects matter most with erythropoiesis-stimulating agents?

Hypertension, thrombosis, stroke and seizures are the key risks with erythropoiesis-stimulating agents such as epoetin alfa. Haemoglobin is kept at the target range and not pushed above it to limit these events.

### Why is G-CSF used in stem cell mobilisation?

G-CSF mobilises CD34-positive haematopoietic stem cells from the marrow into the peripheral blood, allowing collection by apheresis for autologous or allogeneic transplant. The donor is monitored during the mobilisation period.